CNR1 and obesity disorder: Systemic and intracerebroventricular (icv) administration of a CB1 antagonist—rimonabant, which originally was developed as an anti-obesity medication but was subsequently withdrawn from the market—significantly mitigated the LPS-induced hypothermia.